Cell-delivered magnetic nanoparticles caused hyperthermia-mediated increased survival in a murine pancreatic cancer model

Basel, Matthew T.; Balivada, Sivasai; Wang, Hongwang; Shrestha, Tej B.; Seo, Gwi Moon; Pyle, Marla; Abayaweera, Gayani; Dani, Raj Kumar; Koper, Olga B.; Tamura, Masaaki; Chikán, Viktor; Bossmann, Stefan H.; Troyer, Deryl L.

doi:10.2147/ijn.s28344

Cited by 116 publications

(70 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another study, three cycles of hyperthermia using targeted iron oxide nanoparticles increased the survival by 31% in mice with pancreatic cancer. 23 Our results suggest that the efficacy of Dex-LSMO nanoparticles-mediated hyperthermia is comparable to that reported for iron oxide nanoparticles.…”

Section: Discussionsupporting

confidence: 78%

Hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3 nanoparticles: in vivo studies

Haghniaz

Umrani

Paknikar

2016

IJN

View full text Add to dashboard Cite

Purpose The aim of this study was to evaluate radiofrequency-induced dextran-coated lanthanum strontium manganese oxide nanoparticles-mediated hyperthermia to be used for tumor regression in mice. Materials and methods Nanoparticles were injected intra-tumorally in melanoma-bearing C57BL/6J mice and were subjected to radiofrequency treatment. Results Hyperthermia treatment significantly inhibited tumor growth (~84%), increased survival (~50%), and reduced tumor proliferation in mice. Histopathological examination demonstrated immense cell death in treated tumors. DNA fragmentation, increased terminal deoxynucleotidyl transferase-dUTP nick end labeling signal, and elevated levels of caspase-3 and caspase-6 suggested apoptotic cell death. Enhanced catalase activity suggested reactive oxygen species-mediated cell death. Enhanced expression of heat shock proteins 70 and 90 in treated tumors suggested the possible development of “antitumor immunity”. Conclusion The dextran-coated lanthanum strontium manganese oxide-mediated hyperthermia can be used for the treatment of cancer.

show abstract

Section: Discussionsupporting

confidence: 78%

Hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3 nanoparticles: in vivo studies

Haghniaz

Umrani

Paknikar

2016

IJN

View full text Add to dashboard Cite

show abstract

“…17,[38][39][40] Direct intratumoral injections of MNPs followed by induction heating has shown some benefit in controlling tumor growth. 38,[41][42][43][44][45][46][47][48][49] Direct intratumoral injection was used in the first MNP hyperthermia clinical trial treating a prostate cancer using a 100 kHz machine designed for human patients, 50 and later in human glioma trials 51,52 which demonstrated safety and some benefit. Heating was obtained, but due to inhomogeneous MNP distribution, complete tumor eradication was not possible.…”

Section: Introductionmentioning

confidence: 99%

Intravenous magnetic nanoparticle cancer hyperthermia

Huang¹,

Hainfeld²

2013

IJN

105

View full text Add to dashboard Cite

Magnetic nanoparticles heated by an alternating magnetic field could be used to treat cancers, either alone or in combination with radiotherapy or chemotherapy. However, direct intratumoral injections suffer from tumor incongruence and invasiveness, typically leaving undertreated regions, which lead to cancer regrowth. Intravenous injection more faithfully loads tumors, but, so far, it has been difficult achieving the necessary concentration in tumors before systemic toxicity occurs. Here, we describe use of a magnetic nanoparticle that, with a well-tolerated intravenous dose, achieved a tumor concentration of 1.9 mg Fe/g tumor in a subcutaneous squamous cell carcinoma mouse model, with a tumor to non-tumor ratio . 16. With an applied field of 38 kA/m at 980 kHz, tumors could be heated to 60°C in 2 minutes, durably ablating them with millimeter (mm) precision, leaving surrounding tissue intact.

show abstract

“…Furthermore, the absence of any immune response in our mouse model may be significant. A recent study by Basel et al 45 evaluated mouse monocyte/macrophage-like cells as iron carriers that migrate toward disseminated peritoneal pancreatic cancer cells after intraperitoneal injection. They showed an increase in survival time in the AMF-treated mice compared to controls, using a combination of cell labeling and AMF characteristics that resulted in an overall tumor heating of 4°C -similar to that observed in this study.…”

Section: Discussionmentioning

confidence: 99%

Hyperthermia treatment of tumors by mesenchymal stem cell-delivered superparamagnetic iron oxide nanoparticles

Kalber

Ordidge

Southern³

et al. 2016

IJN

View full text Add to dashboard Cite

Magnetic hyperthermia – a potential cancer treatment in which superparamagnetic iron oxide nanoparticles (SPIONs) are made to resonantly respond to an alternating magnetic field (AMF) and thereby produce heat – is of significant current interest. We have previously shown that mesenchymal stem cells (MSCs) can be labeled with SPIONs with no effect on cell proliferation or survival and that within an hour of systemic administration, they migrate to and integrate into tumors in vivo. Here, we report on some longer term (up to 3 weeks) post-integration characteristics of magnetically labeled human MSCs in an immunocompromized mouse model. We initially assessed how the size and coating of SPIONs dictated the loading capacity and cellular heating of MSCs. Ferucarbotran ® was the best of those tested, having the best like-for-like heating capability and being the only one to retain that capability after cell internalization. A mouse model was created by subcutaneous flank injection of a combination of 0.5 million Ferucarbotran-loaded MSCs and 1.0 million OVCAR-3 ovarian tumor cells. After 2 weeks, the tumors reached ~100 µL in volume and then entered a rapid growth phase over the third week to reach ~300 µL. In the control mice that received no AMF treatment, magnetic resonance imaging (MRI) data showed that the labeled MSCs were both incorporated into and retained within the tumors over the entire 3-week period. In the AMF-treated mice, heat increases of ~4°C were observed during the first application, after which MRI indicated a loss of negative contrast, suggesting that the MSCs had died and been cleared from the tumor. This post-AMF removal of cells was confirmed by histological examination and also by a reduced level of subsequent magnetic heating effect. Despite this evidence for an AMF-elicited response in the SPION-loaded MSCs, and in contrast to previous reports on tumor remission in immunocompetent mouse models, in this case, no significant differences were measured regarding the overall tumor size or growth characteristics. We discuss the implications of these results on the clinical delivery of hyperthermia therapy to tumors and on the possibility that a preferred therapeutic route may involve AMF as an adjuvant to an autologous immune response.

show abstract

Cell-delivered magnetic nanoparticles caused hyperthermia-mediated increased survival in a murine pancreatic cancer model

Cited by 116 publications

References 58 publications

Hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3 nanoparticles: in vivo studies

Hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3 nanoparticles: in vivo studies

Intravenous magnetic nanoparticle cancer hyperthermia

Hyperthermia treatment of tumors by mesenchymal stem cell-delivered superparamagnetic iron oxide nanoparticles

Contact Info

Product

Resources

About